Mingyao Liu | Medicine and Health Sciences | Best Researcher Award

Published on by Research Hypothesis

Prof. Mingyao Liu | Medicine and Health Sciences | Best Researcher Award

Prof. Mingyao Liu | Medicine and Health Sciences | Best Researcher Award | Professor | University of Toronto | Canada

Prof. Mingyao Liu, MD, MSc, is an internationally recognized biomedical scientist and academic leader renowned for his pioneering contributions to lung injury, transplantation immunology, and regenerative medicine. He currently serves as the James & Mary Davie Chair in Lung Injury, Repair and Regeneration at the University Health Network and as Director of the Institute of Medical Science at the University of Toronto, where he leads multidisciplinary teams advancing translational research in organ preservation and immunomodulation. Prof. Mingyao Liu obtained his M.D. and M.Sc. in Pathophysiology from the Second Military Medical University in Shanghai, China, followed by an intensive postdoctoral fellowship at the SickKids Research Institute in Toronto, Canada, where he began his journey into molecular mechanisms of lung disease and transplant biology. His professional experience spans decades of leadership roles, including Senior Scientist at the Toronto General Hospital Research Institute and Full Professor in the Department of Surgery at the University of Toronto, with cross-appointments in Medicine and Physiology. Prof. Mingyao Liu’s research interests focus on understanding ischemia-reperfusion injury, immune tolerance in organ transplantation, and cellular mechanisms driving lung regeneration. His laboratory employs advanced molecular biology, gene editing, single-cell transcriptomics, and ex vivo organ perfusion systems to identify therapeutic targets that improve graft survival and repair outcomes. His scientific expertise is further reflected through numerous publications in high-impact journals such as Transplantation, Scientific Reports, NPJ Digital Medicine, and The American Journal of Transplantation. Prof. Mingyao Liu has received multiple prestigious awards, including the Queen Elizabeth II Diamond Jubilee Medal, the Premier’s Research Excellence Award, and the Mel Silverman Mentorship Award, highlighting both his research excellence and commitment to nurturing the next generation of scientists. As a dedicated member of numerous professional societies such as the American Thoracic Society, The Transplantation Society, and the International Society of Heart and Lung Transplantation, he plays a significant role in shaping global biomedical research discourse. Prof. Mingyao Liu’s career reflects a rare combination of innovative science, effective leadership, and lifelong mentorship, making him one of the foremost authorities in lung transplant biology. His continued contributions are shaping the future of regenerative medicine through translational discoveries that bridge laboratory innovation with clinical excellence, reinforcing his position as a global leader dedicated to improving outcomes for patients with severe pulmonary diseases.

Profile: Scopus | ORCID | Google Scholar

Featured Publications

  1. Liu, M. (2025). Permissive immunosuppression facilitates the expansion of ex vivo administered regulatory T cells in the lung allograft. Scientific Reports. 1 citation.

  2. Liu, M. (2025). Ischemia/Reperfusion upregulates genes related to PANoptosis in human lung transplants. Transplantation. 3 citations.

  3. Liu, M. (2025). L-Alanyl-L-Glutamine alleviated ischemia-reperfusion injury and primary graft dysfunction in rat lung transplants. Transplantation. 2 citations.

  4. Liu, M. (2025). Ex vivo delivery of recombinant IL-10 to human donor lungs. JHLT Open. 0 citations.

  5. Liu, M. (2025). Protective effects of 10 °C preservation on donor lungs with lipopolysaccharide-induced acute lung injury. Conference Proceedings. 1 citation.

  6. Liu, M. (2024). Improving prognostic accuracy in lung transplantation using unique features of isolated human lung radiographs. NPJ Digital Medicine. 3 citations.

  7. Liu, M. (2024). Ischemia-reperfusion responses in human lung transplants at the single-cell resolution. American Journal of Transplantation. 5 citations.

 

Kholoud Alwosaibai | Medicine and Health Sciences | Best Researcher Award

Published on by Research Hypothesis

Dr. Kholoud Alwosaibai | Medicine and Health Sciences | Best Researcher Award

Dr. Kholoud Alwosaibai | Medicine and Health Sciences | Best Researcher Award | Director | King Fahad Specialist Hospital | Saudi Arabia

Dr. Kholoud Alwosaibai is a highly accomplished biomedical scientist, cancer geneticist, and immunotherapy specialist with over fifteen years of progressive experience in translational oncology, molecular medicine, and clinical genomics. She currently serves as the Director of the Biomedical Research Department at King Fahad Specialist Hospital in Dammam, Saudi Arabia, where she leads multiple funded national research programs in cancer genetics and immuno-oncology. Dr. Kholoud Alwosaibai earned her Ph.D. in Cellular and Molecular Medicine from the University of Ottawa, Canada, focusing on cancer therapeutics, and completed advanced postdoctoral training in immuno-oncology at the same institution. Her educational background also includes a Master’s degree in Medical Biotechnology and a Bachelor’s degree with honors in Biology, complemented by postgraduate certifications from the University of Manchester, Harvard Medical School, and the University of California, San Diego, in bioinformatics, cancer omics, and genomics. Professionally, Dr. Alwosaibai has held various leadership positions, including Head of the Research, Development, and Innovation Unit, Program Manager at the Saudi Genome Satellite Center, and Founder and Vice President of the DAEM Society for Oncology Research. Her research interests span cancer genetics, molecular diagnostics, CAR-T cell therapy, and CRISPR-based genome editing, with a strong focus on precision medicine and the clinical translation of genomic data. Dr. Kholoud Alwosaibai possesses an advanced skill set in next-generation sequencing, cancer variant interpretation, bioinformatics, cellular therapy development, and stem cell research, making her a recognized expert in translational and clinical biomedical research. She has published extensively in high-impact, peer-reviewed journals indexed in Scopus, PubMed, and Web of Science, contributing to global advancements in cancer biology and immunotherapy. Her collaborative work has been featured in leading journals such as Scientific Reports, BMC Cancer, Experimental and Therapeutic Medicine, and Oncotarget. Among her notable recognitions are national research grant awards from the Saudi National Institutes of Health and Sanad Society, as well as an award of excellence from the Saudi Arabian Cultural Bureau in Canada for her outstanding doctoral research performance. Throughout her career, Dr. Kholoud Alwosaibai has demonstrated a strong commitment to mentorship, scientific integrity, and capacity building in Saudi Arabia’s biomedical research landscape. Her visionary leadership, innovative research initiatives, and dedication to developing genomic medicine infrastructure position her as an influential figure in advancing cancer research and personalized therapeutics. In conclusion, Dr. Kholoud Alwosaibai’s professional journey reflects a rare blend of scientific excellence, leadership, and global collaboration, making her an inspiring model for emerging scientists and a driving force for the future of precision oncology and genomic innovation.

Profile: Scopus | ORCID

Featured Publications 

  1. Alwosaibai, K., Abedini, A., Al-Hujaily, E. M., Tang, Y., Garson, K., Collins, O., & Vanderhyden, B. C. (2017). PAX2 maintains the differentiation of oviductal epithelium and inhibits the transition to a stem cell-like state. Oncotarget. Citations: 85

  2. Gharaibeh, L., Elmadany, N., Alwosaibai, K., & Alshaer, W. (2020). Notch 1 in cancer therapy: Possible clinical implications and challenges. Molecular Pharmacology. Citations: 64

  3. Ghandorah, S., & Alwosaibai, K. (2021). Post-liver transplantation GVHD: Time to consider histocompatibility testing. Journal of Liver Transplantation. Citations: 22

  4. Alwosaibai, K., Al-Hujaily, E. M., Alamri, S., Ghandorah, S., Garson, K., & Vanderhyden, B. C. (2022). PAX2 induces vascular-like structures in normal ovarian cells and ovarian cancer. Experimental and Therapeutic Medicine, 23(6), 412. Citations: 37

  5. Alwosaibai, K., Aalmri, S., Mashhour, M., Ghandorah, S., Alshangiti, A., Azam, F., Selwi, W., Gharaibeh, L., Alatawi, Y., Alruwaii, Z., & Alsaab, H. O. (2023). PD-L1 is highly expressed in ovarian cancer and associated with cancer stem cells populations expressing CD44 and other stem cell markers. BMC Cancer, 23(1), 13. Citations: 41

  6. Alessy, S. A., Almotlak, A. A., Alattas, M., Alshareef, A., Alwosaibai, K., Alghamdi, M. A., Razack, H. I. A., & Alqahtani, S. A. (2024). Cancer research challenges and potential solutions in Saudi Arabia: A qualitative discussion group study. JCO Global Oncology, 10, e2300189. Citations: 18

  7. Alwosaibai, K., Alruwaii, Z. I., Mashhour, M., Almsned, F. M., Asraf, R., Alrsheedy, W., Alessa, A., Almohanna, H., Selwi, W., & Azam, F. (2024). Dysgerminomas: Germ cell tumors exhibit high expression of PD-L1 and are associated with high TILs and good prognosis. Scientific Reports, 14(1), 24191. Citations: 12